Bufalin Inhibits Cytokine Storm by Regulating TLR4/TLR3 Signaling Pathway
Immunity, Inflammation and Disease · 2026-02 · 14 (2)
DOI: 10.1002/iid3.70318 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 04.02.2026. Verfasst von Xixi Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Hospital of Nanjing University of Chinese Medicine, First Clinical Medical College of Nanjing University of Chinese Medicine, Nanjing, Chi…. Hauptthemen laut MEDLINE: Bufanolides, Toll-Like Receptor 4, Signal Transduction, Toll-Like Receptor 3. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Developing Program for High-level Academic Talent in Jiangsu Hospital of Chinese Medicine, Open Project of State Key Laboratory of Medical Immunology.
Abstract (Originalsprache)
Background
Bufalin is one main component of the dried venom from Bufo gargarizans Cantor , which has anti‐tumor, cardiotonic, anti‐inflammatory and other physiological activities. However, in recent years, researchers have mainly paid attention to its anti‐tumor effect and neglected its anti‐inflammatory effect.
Methods
We used lipopolysaccharide (TLR4 ligand) and poly inosinic acid (TLR3 ligand) to stimulate cultured macrophages to induce inflammatory condition. Transcriptome sequencing and molecular experiments were performed to investigate the underlying mechanism.
Results
Bufalin could significantly reduce the production of pro‐inflammatory factors (IL‐6, TNF‐α, IL‐1β, IL‐8, CXCL10, etc.), through inhibiting the phosphorylation of IKBα and IRF3, and thus down‐regulating Toll‐like receptor pathway. Molecular docking predicted that one of the molecular targets of bufalin is MD‐2 coupled with lipopolysaccharide‐activated TLR4.
Conclusion
These findings not only support the pharmacological basis of using toad to treat inflammatory diseases in the Chinese medical history, but also provide a promising anti‐inflammatory drug candidate for future clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Affiliated Hospital of Nanjing University of Chinese Medicine, First Clinical Medical College of Nanjing University of Chinese Medicine, Nanjing, China.
- Department of General Medicine, The People's Hospital of Lianxi District, Jiujiang City, Jiujiang, China.
- Wisdom Lake Academy of Pharmacy, Xi'an Jiaotong-Liverpool University, Suzhou, China.
- Lianshui Hospital of Traditional Chinese Medicine, Huaian, China.
Förderung
- National Natural Science Foundation of China
- Developing Program for High-level Academic Talent in Jiangsu Hospital of Chinese Medicine
- Open Project of State Key Laboratory of Medical Immunology
- Science and Technology Development Program of Jiangsu Province-Clinical Frontier Technology
- Postgraduate Research and Practice Innovation Program of Jiangsu Province
- the Science & Technology Program of Jiangsu Commission of Health
Zitieren
APA
Liu, X., Li, C., Yang, J., Zhang, W., Hu, Z., Zhang, X., Jianati, R., Tian, F., Dai, X., Xu, Z., Chen, B., & Zhu, X. (2026). Bufalin Inhibits Cytokine Storm by Regulating TLR4/TLR3 Signaling Pathway. Immunity, Inflammation and Disease, 14(2). https://doi.org/10.1002/iid3.70318
Vancouver
Liu X, Li C, Yang J, Zhang W, Hu Z, Zhang X, et al. Bufalin Inhibits Cytokine Storm by Regulating TLR4/TLR3 Signaling Pathway. Immunity, Inflammation and Disease. 2026;14(2). doi:10.1002/iid3.70318
BibTeX
@article{Liu2026,
author = {Liu, Xixi and Li, Chencheng and Yang, Jing and Zhang, Weiguang and Hu, Zhongxiao and Zhang, Xiaoli and Jianati, Reaila and Tian, Fang and Dai, Xingbin and Xu, Zuqiong and Chen, Biqing and Zhu, Xuejun},
title = {Bufalin Inhibits Cytokine Storm by Regulating TLR4/TLR3 Signaling Pathway},
journal = {Immunity, Inflammation and Disease},
year = {2026},
volume = {14},
number = {2},
doi = {10.1002/iid3.70318}
}
EUVIMED